Please assess the completion status of the following clinical trial:

Trial Title: Reduced Dose of Pegfilgrastim as Support for Chemotherapy for Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* female aged 18-69 years~* diagnosed pathologically as early breast cancer~* with indication for adjuvant chemotherapy and suitable for AC regimen (epirubicin and cyclophosphamide, or pirarubicin and cyclophosphamide, planned chemotherapy with taxanes after AC regimen were allowed)~* received no prior chemotherapy (chemotherapy naïve)~* have Karnofsky performance status ≥ 80,~* baseline hemoglobin ≥90g/L, white blood cell count ≥4.0X10\^9/L,ANC≥2.0X10\^9/L, platelet count ≥100X10\^9~* adequate cardiac, hepatic and renal function~Exclusion Criteria:~* enrolled onto or had not yet completed other investigational drug trials~* allergic to any component of PEG-rhG-CSF injection, or other biological products derived from genetically engineering Escherichia coli;~* pregnant or lactating women;~* previous large volume radiotherapy, or prior bone marrow or stem-cell transplantation

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- pegfilgrastim 3mg (Type: EXPERIMENTAL): Pegfilgrastim 3mg per chemotherapy cycle
- pegfilgrastim 6mg (Type: ACTIVE_COMPARATOR): Pegfilgrastim 6mg per chemotherapy cycle

Based on this trial design, predict the completion outcome and termination type (if applicable).